{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:17:37Z","timestamp":1787001457842,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2001,8]]},"DOI":"10.1023\/a:1015366923810","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T18:08:17Z","timestamp":1041098897000},"page":"173-178","source":"Crossref","is-referenced-by-count":52,"title":["Minor Tumour Shrinkage in Nonfunctioning Pituitary Adenomas by Long-Term Treatment with the Dopamine Agonist Cabergoline"],"prefix":"10.1007","volume":"4","author":[{"given":"Tobias","family":"Lohmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Trantakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Biesold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Prothmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Guenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Paschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"405301_CR1","first-page":"3395","volume":"80","author":"S Melmed","year":"1995","unstructured":"Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev.med.47.1.95","volume":"47","author":"Y Greenman","year":"1996","unstructured":"Greenman Y, Shlomo M. Diagnosis and management of nonfunctioning pituitary tumors. Ann Rev Med 1996;47: 95.","journal-title":"Ann Rev Med"},{"key":"405301_CR3","first-page":"2338","volume":"81","author":"BMK Biller","year":"1996","unstructured":"Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR4","first-page":"3034","volume":"83","author":"CB Newman","year":"1998","unstructured":"Newman CB, Melmed S, George A, Torgian D, Duhaney M, Snyder P, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR5","first-page":"2779","volume":"86","author":"A Colao","year":"2001","unstructured":"Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR6","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","volume":"83","author":"R Abs","year":"1998","unstructured":"Abs R, Verhelst J, Maiter D, van Acker K, Nobels F, Coolens J-L, et al. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 1998;83: 374.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrin Metab 1999;84:2518.","journal-title":"J Clin Endocrin Metab"},{"key":"405301_CR9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-96-3-281","volume":"96","author":"F Wollesen","year":"1982","unstructured":"Wollesen F, Andersen T, Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Ann Intern Med 1982;96:281.","journal-title":"Ann Intern Med"},{"key":"405301_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1984.60.1.0001","volume":"60","author":"DL Barrow","year":"1984","unstructured":"Barrow DL, Tindall GT, Kovacs K, Thorner MO, Horvath E, Hoffmann JC. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurgery 1984;60:1.","journal-title":"J Neurosurgery"},{"key":"405301_CR11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1210\/jcem-61-3-580","volume":"61","author":"ML Vance","year":"1985","unstructured":"Vance ML, Ridgway EC, Thorner MO. Follicle-stimulating hormone-and \u03b1-subunit-secreting pituitary tumor treated with bromocriptine. J Clin Endocrinol Metab 1985;61:580.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2265.1986.tb03625.x","volume":"25","author":"MC D'Emden","year":"1986","unstructured":"D'Emden MC, Harrison LC. Rapid improvement in visual field defects follwing bromocriptine treatment of patients with nonfunctioning pituitary adenomas. Clin Endocrinol 1986;25:697.","journal-title":"Clin Endocrinol"},{"key":"405301_CR13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2265.1985.tb03004.x","volume":"22","author":"A Grossmann","year":"1985","unstructured":"Grossmann A, Ross R, Charlesworth M, Adams CBT, Wass JAH, Doniach I, et al. The effect of dopamine agonist therapy on large functionless pituitary tumors. Clin Endocrinol 1985;22:679.","journal-title":"Clin Endocrinol"},{"key":"405301_CR14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2265.1986.tb03610.x","volume":"25","author":"JS Bevan","year":"1986","unstructured":"Bevan JS, Burke CW. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol 1986;25:561.","journal-title":"Clin Endocrinol"},{"key":"405301_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2265.1992.tb00953.x","volume":"36","author":"DJ Kwekkeboom","year":"1992","unstructured":"Kwekkeboom DJ, Lamberts SWJ. Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or \u03b1-subunit secreting pituitary adenoma. Clin Endocrinol 1992;36:171.","journal-title":"Clin Endocrinol"},{"key":"405301_CR16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/eje.0.1430615","volume":"143","author":"FRE Nobels","year":"2000","unstructured":"Nobels FRE, de Herder WW, van den Brink WM, Kwekkeboom DJ, Hofland LJ, Zuyderwijk J, et al. Longterm treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. Eur J Endocrinol 2000;143:615.","journal-title":"Eur J Endocrinol"},{"key":"405301_CR17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1210\/jcem.83.1.4493","volume":"83","author":"D Ferone","year":"1998","unstructured":"Ferone D, Lastoria S, Colao A, Varella P, Cerbone G, Acampa W, et al. Correlation of scintigraphic results using 123IMethoxybenzamide with hormone levels and tumor size response to Quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 1998;83:248.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","volume":"53","author":"A Di Sarno","year":"2000","unstructured":"Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, et al. The effect of quinagolide and cabergoline, two selective dopamin receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol 2000;53:53.","journal-title":"Clin Endocrinol"},{"key":"405301_CR19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-2265.2000.00951.x","volume":"52","author":"A Colao","year":"2000","unstructured":"Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, et al. Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: Predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol 2000;52:437.","journal-title":"Clin Endocrinol"},{"key":"405301_CR20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2265.2001.01172.x","volume":"54","author":"M Andersen","year":"2001","unstructured":"Andersen M, Bjerre P, Schroder HD, Edal A, Hoilund-Carlsen PF, Pedersen PH, et al. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol 2001;54:23.","journal-title":"Clin Endocrinol"},{"key":"405301_CR21","first-page":"784","volume":"77","author":"FRE Nobels","year":"1993","unstructured":"Nobels FRE, Kwekkeboom DJ, Coopmans W, Hoekstra R, De Herder WW, Bouillon R, et al. A comparison between the diagnostic value of gonadotropins, \u03b1-subunit and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, \u03b1-subunit-secreting, and gonadotroph pituitary adenomas. J Clin Endocrinol Metab 1993;77:784.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJM199102283240904","volume":"324","author":"L Daneshdoost","year":"1991","unstructured":"Daneshdoost L, Gennarelli TA, Bashey HM, Savino PJ, Sergott RC, Bosley TM, et al. Recognition of gonadotroph adenomas in women. N Engl J Med 1991;324:589.","journal-title":"N Engl J Med"},{"key":"405301_CR23","first-page":"1352","volume":"77","author":"L Daneshdoost","year":"1993","unstructured":"Daneshdoost L, Gennarelli TA, Bashey HM, Savino PJ, Sergott RC, Bosley TM, et al. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone \u03b2 subunit response to thyrotropinreleasing hormone. J Clin Endocrinol Metab 1993;77:1352.","journal-title":"J Clin Endocrinol Metab"},{"key":"405301_CR24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1365-2265.1997.1720986.x","volume":"46","author":"D Somjen","year":"1997","unstructured":"Somjen D, Tordjman K, Kohen F, Baz M, Razon N, Ouaknine G, et al. Combined \u03b2FSH and \u03b2LH response to TRH in patients with clinically nonfunctioning pituitary adenomas. Clin Endocrinol 1997;46:555.","journal-title":"Clin Endocrinol"},{"key":"405301_CR25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3171\/jns.1992.77.1.0151","volume":"77","author":"H Duong","year":"1992","unstructured":"Duong H, Rostomily RC, Haynor DR, Keles GE, Berger MS. Measurement of tumor resection volumes from computerized images. J Neurosurgery 1992;77:151.","journal-title":"J Neurosurgery"},{"key":"405301_CR26","first-page":"2247","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2247.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1015366923810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1015366923810\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1015366923810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T04:48:37Z","timestamp":1754282917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1015366923810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["405301"],"URL":"https:\/\/doi.org\/10.1023\/a:1015366923810","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}